Evidence map›Paper›PMID 29190732›Full record

ArticlePloS one2017

Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation.

Linghong Shen, Zhe Sun, Shichun Chu, Zhaohua Cai, Peng Nie, Caizhe Wu, Ruosen Yuan, Liuhua Hu, Ben He

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Clinical pharmacology : advances and applications · 2025
    Review
  5. Emerging role of IRE1α in vascular diseases.Journal of cell communication and signaling · 2024
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Linghong ShenDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhe SunDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shichun ChuDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhaohua CaiDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Peng NieDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Caizhe WuDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Ruosen YuanDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Liuhua HuDepartment of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Ben HeDepartment of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-5567-4115
Renji Hospital · CNShanghai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xuezhikang (XZK), an extract of red yeast rice, is a traditional Chinese medicine widely used for the treatment of cardiovascular diseases in China and other countries. However, whether XZK treatment can improve atherosclerotic plaque stability is not fully understood. Based on our previously developed mouse model of spontaneous vulnerable plaque formation and rupture in carotid arteries in ApoE-/- mice. We showed that low-dose (600 mg/kg/d) XZK improved plaque stability without decreasing plaque area, whereas high-dose (1200 mg/kg/d) XZK dramatically inhibited vulnerable plaque progression accompanied by decreased plaque area. Mechanistically, XZK significantly suppressed lesional endoplasmic reticulum (ER) stress in mouse carotid arteries. In vitro, XZK inhibited 7-KC-induced activation of ER stress in RAW264.7 macrophages, as assessed by the reduced levels of p-PERK, p-IRE1α, p-eIF2α, c-ATF6, s-XBP1, and CHOP. Compared to controls, the XZK-treated group displayed dramatically decreased apoptotic cell numbers (shown by decreased TUNEL- and cleaved caspase3-positive cells), lower necrotic core area and ratio, and reduced expression of NF-κB target gene. In RAW264.7 cells, XZK inhibited 7-KC-induced upregulation of apoptosis, protein expression of apoptotic markers (cleaved caspase-3 and cleaved PARP), and NF-κB activation (shown by target gene transcription and IκBα reduction). Collectively, our results suggest that XZK effectively suppresses vulnerable plaque progression and rupture by mitigating macrophage ER stress and consequently inhibiting apoptosis and the NF-κB pro-inflammatory pathway, thereby providing an alternative therapeutic strategy for stabilizing atherosclerotic plaques.

Indexed as

AnimalsApolipoproteins EApoptosisBiological ProductsDisease ProgressionDrugs, Chinese HerbalEndoplasmic Reticulum StressInflammationMiceMice, KnockoutNF-kappa BPlaque, AtheroscleroticRAW 264.7 CellsReverse Transcriptase Polymerase Chain ReactionSignal TransductionApolipoproteins EBiological ProductsDrugs, Chinese HerbalNF-kappa Bred yeast ricexuezhikang

Identifiers

PMID29190732
PMCPMC5708751
OpenAlexW2772607919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.